tirzepatide for cardiovascular disease In patients with type 2 diabetes and atherosclerotic disease, was noninferior to dulaglutide with respect to major cardiovascular events. Read the full SURPASS-CVOT trial Original Article: Cardiovascular Outcomes with
Pay in 4 interest-free payments of $6.20 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29





















